Response to the Letter to the Editor by M. J. Gallimore et al

References
1 Gallimore MJ, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein “like” activity in human plasma. Thromb Res 1982; 25: 293-298
2 Kabi Diagnostica, Stockholm, Sweden, Product Information Bull 1990/91.
3 Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Meth Enzymol 1981; 80: 341-361
4 Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. α₂-Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660-2667
5 Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-1729
6 De Agostini A, Linjen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J Clin Invest 1984; 73: 1542-1549
7 Schapira M. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemostas 1987; 13: 69-78
8 Harpel PC, Lewin MF, Kaplan AP. Distribution of plasma kallikrein between C1-inactivator and α₂-macroglobulin in plasma utilizing a new assay for α₂-macroglobulin-kallikrein complexes. J Biol Chem 1985; 260: 4257-4263
9 Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E. Studies on the inhibition of plasma kallikrein, C1-esterase and beta FXIIa in the presence and absence of heparins. In: Kinins V. Advances in Experimental Medicine and Biology. Plenum Press; New York: 1989. 247 61-66
10 Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by C1-inhibitor. Arch Biochem Biophys 1987; 256: 490-498
11 Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of factor XII and the contact system. Thromb Haemostas 1991; 66: 540-547
12 Gallimore MJ, Fuhrer G, Heller W, Hoffmeister H-E. The effects of fractionated and unfractionated heparins with and without aprotinin on plasma inhibition of alpha and beta FXIIa KININ 91. Munich, Germany 1991 abstract PW-3.14, 226
13 Gallimore MJ, Fuhrer G, Heller W, Hoffmeister H-E. The effects of plasma kallikrein and beta FXIIa (FXIIf) on blood components circulating in a cardiopulmonary bypass machine. Thromb Haemostas 1989; 62: 268
14 Heller W, Wendel HP, Klaffschenkel R, Hoffmeister H-E. A comparative study of fractionated and unfractionated heparins on components of the FXII-plasma kallikrein system in an in vitro cardiopulmonary bypass model. KININ 91, Munich, Germany 1991. abstract PW-3.15, 227
15 Wachtfogel YT. Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH Jr et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-330
16 Wachtfogel YT, Harpel PC, Edmunds LHJr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-α2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-471
17 Wachtfogel YT, Kucich U, Hack CE, Niewiarowski S, Colman RW, Edmunds Jr LH. Aprotinin partially inhibits the contact and platelet activation systems during extracorporeal perfusion. J Thoracic and Cardiovascular Surgery 1992 (in press)
18 Hunt BJ, Jacoub M. Aprotinin and cardiac surgery. Br Med J 1991; 303: 660-661